Hematology — MCQs

A 7-year-old boy has severe microcytic anemia due to beta-thalassemia major (homozygous). He requires frequent blood transfusions to prevent skeletal and developmental complications. Which of the following medications is also indicated in the treatment of patients requiring frequent blood transfusions?

Q837Easy

What is the most common site of histiocytosis?

Q838Easy

Platelet transfusions must be completed within how many hours after the blood bag is issued from the blood bank?

Q839Easy

A patient presents with Hb of 8 gm%, WBC count of 2000/mm3 and platelet count of 60000/mm3. What is your likely diagnosis?

Q840Medium

What is the standard treatment regimen for Hodgkin's disease?

Hematology Indian Medical PG Practice Questions and MCQs

Question 831: Which stage of erythroid maturation is characterized by the presence of the 'Die' nucleus?

A. M1 AML
B. M2 AML
C. M3 AML (Correct Answer)
D. M4 AML

Explanation: **Explanation:** The term **'Die' nucleus** (or 'dice' nucleus) refers to the characteristic nuclear morphology seen in **Acute Promyelocytic Leukemia (APL)**, classified as **M3 AML** in the French-American-British (FAB) system [1]. **1. Why M3 AML is Correct:** In APL, the malignant cells are promyelocytes. These cells often exhibit a **bilobed, reniform (kidney-shaped), or "butterfly" nucleus** that resembles the faces of a die. This is a high-yield morphological marker alongside the presence of **Auer rods**, which are often found in bundles called **Faggot cells**. The underlying molecular pathology is the **t(15;17)** translocation, involving the PML-RARA fusion gene [1]. **2. Why Other Options are Incorrect:** * **M1 AML (Minimal Maturation):** Characterized by myeloblasts with negligible maturation and rare Auer rods. The nuclei are typically round to oval, not "die-shaped." * **M2 AML (With Maturation):** Shows significant maturation beyond the blast stage. While Auer rods are common, the classic "die" nucleus is not a defining feature [1]. * **M4 AML (Acute Myelomonocytic Leukemia):** Characterized by both myeloid and monocytic lineages. Monocytic cells have folded or indented nuclei, but they lack the specific "die" appearance of M3. **3. High-Yield Clinical Pearls for NEET-PG:** * **Emergency:** M3 AML is a medical emergency due to the high risk of **DIC (Disseminated Intravascular Coagulation)** triggered by the release of procoagulants from granules. * **Treatment:** The mainstay of treatment is **ATRA (All-trans retinoic acid)** and Arsenic Trioxide, which force the differentiation of promyelocytes. * **Cytogenetics:** Always associate M3 with **t(15;17)** [1].

Question 832: Acute Myeloid Leukemia (AML) transformation is most common in which of the following conditions?

A. Aplastic anemia (Correct Answer)
B. Myelodysplastic syndromes (MDS)
C. Megakaryocytic thrombocytopenia
D. None of the above

Explanation: **Explanation:** **1. Why Aplastic Anemia is the Correct Answer:** Aplastic Anemia (AA) is a bone marrow failure syndrome characterized by pancytopenia and a hypocellular marrow. While it is primarily an immune-mediated destruction of hematopoietic stem cells, it is considered a **pre-leukemic state**. Long-term survivors of AA, especially those treated with immunosuppressive therapy (IST) rather than bone marrow transplant, have a significant risk of clonal evolution. Approximately **10-15%** of patients with AA eventually transform into **Acute Myeloid Leukemia (AML)** or Myelodysplastic Syndrome (MDS). This transformation is often associated with specific cytogenetic abnormalities, most commonly **Monosomy 7**. **2. Analysis of Incorrect Options:** * **Option B: Myelodysplastic Syndromes (MDS):** While MDS is a classic precursor to AML (often called "pre-leukemia"), the question asks which condition *transforms* into AML most commonly among the choices provided [1]. In many clinical contexts and competitive exams like NEET-PG, AA is highlighted for its high-risk clonal evolution into AML as a late complication of the disease process itself. * **Option C: Megakaryocytic thrombocytopenia:** This refers to conditions like Immune Thrombocytopenic Purpura (ITP) where megakaryocytes are present but platelets are destroyed peripherally. These are not stem cell disorders and do not carry an inherent risk of transformation into AML. **3. NEET-PG High-Yield Pearls:** * **Clonal Evolution:** The most common late complications of Aplastic Anemia are PNH (Paroxysmal Nocturnal Hemoglobinuria), MDS, and AML. * **Cytogenetics:** Transformation of AA to AML is frequently linked to **Monosomy 7**. * **Fanconi Anemia:** Among inherited bone marrow failure syndromes, Fanconi Anemia has the highest risk of AML transformation. * **Treatment Note:** Bone marrow transplant is curative and reduces the risk of secondary AML compared to IST.

Question 833: A 25-year-old female presents with complaints of fever and weakness. On examination, there is splenomegaly of 3 cm below the costal margin. Her Hb is 8 gm/dL, TLC is 3,000/mm3, and platelet count is 80,000 mm3. Which of the following is the least likely diagnosis?

A. Acute lymphocytic leukemia
B. Anemia of chronic disease
C. Aplastic anemia (Correct Answer)
D. Megaloblastic anemia

Explanation: ### Explanation The patient presents with **pancytopenia** (anemia, leucopenia, and thrombocytopenia) and **splenomegaly**. The key to solving this question lies in the clinical finding of an enlarged spleen [1]. **1. Why Aplastic Anemia is the Correct Answer (Least Likely):** Aplastic anemia is characterized by bone marrow failure leading to pancytopenia. A fundamental clinical rule in hematology is that **Aplastic Anemia does not cause splenomegaly.** If a patient with pancytopenia has an enlarged spleen, the clinician must look for alternative diagnoses like leukemia, myelofibrosis, or hypersplenism [2]. The presence of splenomegaly in a suspected case of aplastic anemia should prompt a search for an "infiltrative" cause rather than primary marrow failure. **2. Analysis of Other Options:** * **Acute Lymphocytic Leukemia (ALL):** This is a common cause of pancytopenia due to marrow infiltration by blasts. Splenomegaly is a frequent finding in ALL due to extramedullary involvement. * **Anemia of Chronic Disease (ACD):** While typically presenting as isolated anemia, chronic inflammatory states or infections (like Tuberculosis or Kala-azar) can cause both cytopenias and reactive splenomegaly. * **Megaloblastic Anemia:** Severe Vitamin B12 or Folate deficiency leads to ineffective erythropoiesis, often resulting in pancytopenia. Mild to moderate splenomegaly is seen in about 10–15% of these cases. **3. Clinical Pearls for NEET-PG:** * **Pancytopenia + Splenomegaly:** Think of Malaria, Kala-azar, Leukemia, Lymphoma, Cirrhosis (Portal Hypertension), or Gaucher’s disease. * **Pancytopenia - Splenomegaly:** Think of Aplastic Anemia, PNH (Paroxysmal Nocturnal Hemoglobinuria), or early-stage Myelodysplastic Syndrome (MDS). * **Gold Standard:** The definitive investigation to differentiate these conditions is a **Bone Marrow Aspiration and Biopsy**. In Aplastic Anemia, the marrow will be "hypocellular" with increased fat spaces.

Question 834: What is the basic defect in Hemoglobin S?

A. Altered function
B. Altered solubility (Correct Answer)
C. Altered stability
D. Altered oxygen binding capacity

Explanation: ### Explanation The fundamental defect in **Hemoglobin S (HbS)** is a qualitative change in the beta-globin chain, where **glutamic acid** (polar/hydrophilic) is replaced by **valine** (non-polar/hydrophobic) at the **6th position** [1]. **1. Why "Altered Solubility" is Correct:** The substitution of a hydrophobic amino acid (valine) creates a "sticky patch" on the surface of the hemoglobin molecule. In the **deoxygenated state**, these patches interact, causing HbS molecules to polymerize into long, rigid insoluble fibers [2]. This **polymerization** (decreased solubility) distorts the red blood cell into a sickle shape, leading to vaso-occlusion and hemolysis. **2. Analysis of Incorrect Options:** * **Altered Function:** While the clinical outcome is dysfunctional, the "basic defect" refers to the physical property change (solubility) that precedes the functional failure. * **Altered Stability:** This refers to **unstable hemoglobins** (e.g., Hb Koln) that precipitate as Heinz bodies. HbS is stable until it deoxygenates. * **Altered Oxygen Binding Capacity:** This is characteristic of **Hemoglobin M** (methemoglobinemia) or high-affinity variants (e.g., Hb Chesapeake) [3]. HbS actually has a *decreased* oxygen affinity (right shift of the dissociation curve), but this is a secondary effect, not the primary defect. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Autosomal Recessive; Point mutation (Missense) in the HBB gene on Chromosome 11. * **Sickling Triggers:** Hypoxia, acidosis, dehydration, and cold. * **Protective Factor:** HbF (Fetal Hemoglobin) inhibits polymerization; hence, Hydroxyurea (which increases HbF) is the treatment of choice. * **Metabolic Benefit:** Heterozygotes (Sickle cell trait) have a survival advantage against *Plasmodium falciparum* malaria.

Question 835: All are important laboratory features of hereditary spherocytosis, EXCEPT:

A. Reduced MCHC (Correct Answer)
B. Normocytic anemia
C. Positive pink test
D. Normal WBC count

Explanation: In Hereditary Spherocytosis (HS), the primary defect lies in the red cell membrane proteins (most commonly **Ankyrin**, followed by Spectrin) [2], leading to a loss of membrane surface area. **Explanation of the Correct Answer:** * **Option A (Reduced MCHC):** This is the correct answer because it is **false**. In HS, the loss of membrane surface area relative to the volume results in the formation of spherical cells (spherocytes) [1]. These cells are dehydrated, leading to a relative increase in hemoglobin concentration within the cell. Therefore, **MCHC is typically increased (>36 g/dL)**, not reduced [1]. An elevated MCHC is a classic hallmark of HS. **Explanation of Incorrect Options:** * **Option B (Normocytic anemia):** While spherocytes appear small, their MCV is usually within the normal range or slightly low (80-100 fL) because the reticulocytosis (immature, larger RBCs) compensates for the smaller spherocytes. * **Option C (Positive Pink Test):** The "Pink Test" is a simplified version of the Glycerol Lysis Test. It measures the rate of hemolysis; spherocytes lyse more rapidly than normal cells in an acidic glycerol solution, yielding a positive result. * **Option D (Normal WBC count):** HS is a primary disorder of the RBC membrane. Unless there is a secondary infection or an acute crisis, the white blood cell and platelet counts remain normal. **High-Yield Clinical Pearls for NEET-PG:** 1. **Gold Standard Test:** Eosin-5-maleimide (EMA) binding test (Flow cytometry). 2. **Classic Triad:** Anemia, Jaundice, and Splenomegaly. 3. **Peripheral Smear:** Spherocytes (lack central pallor) and Polychromasia (due to reticulocytosis). 4. **Complications:** Pigment gallstones (calcium bilirubinate) and Aplastic crisis (associated with Parvovirus B19). 5. **Treatment of Choice:** Splenectomy (usually deferred until after age 6 to reduce sepsis risk) [2].

Question 836: A 7-year-old boy has severe microcytic anemia due to beta-thalassemia major (homozygous). He requires frequent blood transfusions to prevent skeletal and developmental complications. Which of the following medications is also indicated in the treatment of patients requiring frequent blood transfusions?

A. Oral calcium supplements
B. Fresh frozen plasma (FFP)
C. Desferrioxamine (Correct Answer)
D. Penicillamine

Explanation: **Explanation:** The patient has **Beta-Thalassemia Major**, a condition characterized by ineffective erythropoiesis and severe anemia requiring lifelong regular blood transfusions. The primary complication of chronic transfusion therapy is **Secondary Hemochromatosis (Iron Overload)**. Since the human body lacks an active mechanism to excrete excess iron, each unit of blood (containing ~200mg of iron) contributes to systemic deposition, leading to multi-organ damage (heart, liver, and endocrine glands) [2]. **Why Desferrioxamine is correct:** **Desferrioxamine** is a high-affinity **iron-chelating agent**. It binds to free iron and ferritin-bound iron to form ferrioxamine, which is then excreted via the kidneys and bile. It is indicated when serum ferritin levels exceed 1,000 ng/mL or after the patient has received approximately 10–20 transfusions. **Why other options are incorrect:** * **Oral calcium supplements:** While patients with thalassemia may develop hypoparathyroidism or osteoporosis due to iron deposition, calcium is not a primary treatment for transfusion-related complications. * **Fresh frozen plasma (FFP):** FFP is used to replace clotting factors in coagulopathies; it has no role in treating thalassemia or iron overload. * **Penicillamine:** This is a chelating agent used primarily for **Copper** (Wilson’s disease) and sometimes in rheumatoid arthritis or cystinuria, not for iron overload [1]. **NEET-PG High-Yield Pearls:** * **Routes of Administration:** Desferrioxamine is given SC/IV (poor oral bioavailability). **Deferasirox** and **Deferiprone** are preferred oral alternatives. * **Side Effects:** Desferrioxamine can cause ototoxicity (high-frequency hearing loss) and retinal toxicity. * **Cause of Death:** The most common cause of death in inadequately chelated Thalassemia Major patients is **Heart Failure** (due to siderotic cardiomyopathy).

Question 837: What is the most common site of histiocytosis?

A. Bone (Correct Answer)
B. Skin
C. Lung
D. Liver

Explanation: Langerhans Cell Histiocytosis (LCH) is a rare proliferative disorder of dendritic (Langerhans) cells. For NEET-PG, it is crucial to recognize that LCH can present as a single-system or multi-system disease. **1. Why Bone is the Correct Answer:** The **bone** is the most frequently involved organ in LCH, affected in approximately **80% of cases**. The most common site within the skeletal system is the **skull** (calvarium), followed by the femur, ribs, and mandible. Radiographically, these appear as "punched-out" lytic lesions without a sclerotic rim. In the mandible, it often causes the characteristic "floating teeth" appearance. **2. Why Other Options are Incorrect:** * **Skin:** This is the second most common site (approx. 30–40%). It often presents as a seborrheic dermatitis-like rash, particularly in infants (Letterer-Siwe disease). * **Lung:** While common in adult smokers (Pulmonary LCH), it is less frequent than bone involvement across the general population. * **Liver:** Involvement of the liver, spleen, or hematopoietic system signifies "high-risk" organ involvement and carries a poorer prognosis, but these are not the most common sites. **Clinical Pearls for NEET-PG:** * **Pathognomonic Marker:** **Birbeck granules** (tennis-racket shaped) seen on Electron Microscopy. * **Immunohistochemistry (IHC):** Positive for **CD1a, S100, and CD207 (Langerin)**. * **Hand-Schüller-Christian Triad:** Lytic bone lesions, exophthalmos, and diabetes insipidus. * **BRAF V600E mutation** is identified in about 50% of cases.

Question 838: Platelet transfusions must be completed within how many hours after the blood bag is issued from the blood bank?

A. 1 hour
B. 2 hours
C. 3 hours
D. 4 hours (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. 4 hours** **Medical Rationale:** The primary reason for the strict 4-hour time limit for completing a platelet transfusion is the **risk of bacterial contamination**. Unlike Red Blood Cells (RBCs), which are stored at 2–6°C, platelets are stored at room temperature (20–24°C) with continuous agitation. This warmer environment is highly conducive to the rapid proliferation of bacteria. Once the blood bag is issued and the "cold chain" or controlled environment is breached, the risk of septic transfusion reactions increases significantly. To minimize this risk, international guidelines (including AABB and WHO) mandate that the infusion must be completed within 4 hours. **Analysis of Incorrect Options:** * **Option A (1 hour):** While platelets should be started as soon as possible (ideally within 30 minutes of issue), 1 hour is too restrictive for the total infusion time, especially in patients at risk of volume overload. * **Option B & C (2-3 hours):** Although most platelet transfusions are completed within 30–60 minutes, these timeframes do not represent the maximum safety limit established by transfusion medicine protocols. **High-Yield Clinical Pearls for NEET-PG:** * **Storage:** Platelets are stored at **20–24°C** with constant agitation to prevent aggregation and maintain viability. * **Shelf Life:** They have the shortest shelf life of all blood components, typically only **5 days**. * **Filter:** Must be administered through a standard **170–200 micron** filter. * **Dose Response:** One unit of random donor platelets (RDP) typically increases the platelet count by **5,000–10,000/µL** in a 70kg adult. * **Complication:** Platelets are the blood component most commonly associated with **transfusion-transmitted bacterial sepsis** [1].

Question 839: A patient presents with Hb of 8 gm%, WBC count of 2000/mm3 and platelet count of 60000/mm3. What is your likely diagnosis?

A. Thalassemia
B. Sickle cell anemia
C. Aplastic anemia (Correct Answer)
D. Anemia of chronic disease

Explanation: ### Explanation The clinical presentation described is **Pancytopenia**, which is defined as a simultaneous decrease in all three peripheral blood cell lines: * **Anemia:** Hb 8 gm% (Normal: 13–15 gm%) * **Leukopenia:** WBC 2000/mm³ (Normal: 4,000–11,000/mm³) * **Thrombocytopenia:** Platelets 60,000/mm³ (Normal: 1.5–4.5 lakh/mm³) **Why Aplastic Anemia is the correct diagnosis:** Aplastic anemia is a bone marrow failure syndrome characterized by a hypocellular marrow where hematopoietic stem cells are replaced by fat. This leads to a definitive reduction in the production of RBCs, WBCs, and platelets, resulting in the pancytopenia seen in this patient. **Analysis of Incorrect Options:** * **A. Thalassemia:** This is a microcytic hypochromic anemia caused by defective globin chain synthesis. While it causes low Hb, it does not typically affect WBC or platelet counts unless complicated by massive splenomegaly (hypersplenism). * **B. Sickle Cell Anemia:** This is a hemolytic anemia characterized by abnormal HbS. It presents with anemia and vaso-occlusive crises, but WBC and platelet counts are usually normal or even elevated (leukocytosis) during crises [1]. * **D. Anemia of Chronic Disease:** This is typically a normocytic or microcytic anemia associated with chronic inflammation. It does not cause a decrease in other cell lines; in fact, it may be associated with thrombocytosis (elevated platelets) as an acute-phase reactant. **NEET-PG High-Yield Pearls:** 1. **Gold Standard Diagnosis:** Bone marrow aspiration and biopsy (showing "dry tap" and fatty replacement). 2. **Most Common Cause:** Idiopathic (Immune-mediated T-cell destruction of stem cells). 3. **Drug-induced:** Chloramphenicol is the most notorious drug associated with aplastic anemia. 4. **Clinical Clue:** In aplastic anemia, there is typically **no splenomegaly**. If pancytopenia is present *with* splenomegaly, consider conditions like Cirrhosis (portal hypertension), Leishmaniasis (Kala-azar), or Hematologic malignancies.

Question 840: What is the standard treatment regimen for Hodgkin's disease?

A. CHOP
B. MOPP
C. ABVD (Correct Answer)
D. None of the above

Explanation: **Explanation:** **ABVD** is currently the gold standard first-line chemotherapy regimen for Hodgkin Lymphoma (HL) due to its high efficacy and lower toxicity profile compared to older regimens [1]. It consists of **Adriamycin (Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine**. This regimen is preferred because it achieves high cure rates (70-80%) while minimizing long-term risks such as secondary malignancies (leukemia) and infertility. **Analysis of Options:** * **CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone):** This is the standard treatment for **Non-Hodgkin Lymphoma (NHL)**, specifically Diffuse Large B-Cell Lymphoma (DLBCL). It is not the primary choice for Hodgkin’s disease. * **MOPP (Mechlorethamine, Oncovin, Procarbazine, Prednisone):** This was the first effective combination therapy for HL. However, it has been largely replaced by ABVD because MOPP is associated with significant long-term side effects, including **permanent sterility** and a high risk of **Secondary Acute Myeloid Leukemia (AML)**. **High-Yield Clinical Pearls for NEET-PG:** 1. **Toxicity Monitoring:** * **Adriamycin:** Cardiotoxicity (monitor with ECHO/MUGA scan). * **Bleomycin:** Pulmonary fibrosis (monitor with Pulmonary Function Tests/DLCO). * **Vinblastine:** Peripheral neuropathy and bone marrow suppression. 2. **Staging:** The **Ann Arbor Staging System** is used for HL [1]. 3. **Prognosis:** The presence of **Reed-Sternberg cells** (Owl-eye appearance) is the diagnostic hallmark [1]. 4. **Refractory Cases:** For patients who fail ABVD, the **BEACOPP** regimen or Autologous Stem Cell Transplant may be considered. **Brentuximab Vedotin** (anti-CD30) is a targeted therapy used in relapsed cases.

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?